title: Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?
abstract: With the recent approval by the FDA of an immunotherapy for prostate cancer and another positive immunotherapy trial in melanoma, immunotherapy may finally be coming of age. So what will it take for it to become part of the standard treatment for glioblastoma? To put this question into perspective, we summarize critical background information in neuro-immunology, address immunotherapy clinical trial design, and discuss a number of extrinsic factors that will impact the development of immunotherapy in neuro-oncology.
authors.affiliation: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Unit 442, FC7.3021, Houston, TX 77030-4009, USA. aheimber@mdanderson.org
authors.forename: Amy B
authors.initials: AB
authors.lastname: Heimberger
authors.forename: John H
authors.initials: JH
authors.lastname: Sampson
mesh_terms: D001932:Brain Neoplasms / Q000628:therapy*; D005909:Glioblastoma / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D059039:Standard of Care